RNA Supply Chain Videos

31. CMC Innovations Worth Watching In The RNA-LNP Space 12/4/2024

    Sanofi’s Sumit Luthra shares several of the analytical and manufacturing innovations/improvements he’s watching and waiting for that will improve our knowledge of LNP composition, structure, function, and quality.

32. Why We Still Haven't Solved mRNA Scale-Up 10/15/2025

    While we can make lots of mRNA at a smaller scale, when it comes to scaling up to kg quantities of mRNA, our current batch processes leave a lot to be desired. Together, Stu Sundseth of Tune Therapeutics and Christian Dohmen of Ethris unpack the biggest barriers to scaling IVT to achieve the desired yield and quality of mRNA, offering their take on how the field is innovating to overcome these issues. 

33. Assessing The Quality & Maturity Of The Next-Gen Oligo Supply Chain 12/3/2025

    As our molecules grow more complicated, so, too, does the supply chain. Here, Advancing RNA Live speakers Khaled Yamout & Camp4’s Satya Kuchimanchi talk through how this growth challenges our understanding of raw material quality and how sponsors can better assess their suppliers.

34. The Evolving CMC Landscape For mRNA-LNPs 2/24/2026

    In this Advancing RNA Live clip, CMC consultant Sujit Jain unpacks the levels of maturity he’s observed in process and analytical development, as well as supply chain. While vaccines and liver-targeting therapeutics boast what we can call a reproducible platform today, targeted LNP therapies introduce a handful of scale-up sensitivities and characterization hurdles.

35. The Road To Metric-Ton siRNA Production: Is Enzymatic Ligation Ready For Commercial Volume? 3/27/2026

    Can we actually achieve metric-ton siRNA production today using enzymatic ligation? While the ligation step is highly scalable, upstream "blockmer" synthesis remains the primary bottleneck. Advancing RNA Live panelists Claire McCleod and Jill Caswell discuss the shift from "scaling out" to "scaling up" and lessons learned in the process of achieving larger scale production. 

36. Evaluation Criteria Of Freezer Systems For Bulk Pharmaceuticals 11/1/2023

    Review data and evidence that demonstrates the benefits of an integrated approach to achieving critical end-user goals such as scalability, efficiency, sustainability, and optimized process economics.

37. The 3 C's Of mRNA-LNP Material Sourcing

    In response to an audience poll question gauging which cGMP materials have proven the most difficult to source, our speakers provide additional clarity around which IVT & LNP-related materials today are more “commoditized”.

38. End-To-End Cold Chain Management: A Next-Generation Approach 2/26/2024

    Three experts in cold chain management walk through the advantages of end-to-end platforms for bulk drug substance management.

39. The Purification Dilemma: Balancing Upstream & Downstream Investment 10/15/2025

    This Advancing RNA Live clip dives into the biggest challenges in mRNA purification and the critical debate on where to focus investment. Here, our three mRNA PD experts argue for a holistic process development strategy, challenging the traditional wisdom of optimizing the upstream process at any cost.

40. The Price of Progress: Unlocking Cost Efficiencies in mRNA-LNP Production 4/11/2025

    In this final segment of an Advancing RNA Live discussion, panelists April Sena, Tyler Goodwin, and Adi Nair share the most meaningful and manageable improvements the industry can be making today to upstream and downstream processes to drive down mRNA-LNP COGS.In this final segment of an Advancing RNA Live discussion, panelists April Sena, Tyler Goodwin, and Adi Nair share the most meaningful and manageable improvements the industry can be making today to upstream and downstream processes to drive down mRNA-LNP COGS.